A Case Report of Prenatal Exposure to Rosuvastatin and Telmisartan

Statins are considered to be a standard treatment for hyperlipidemia. Central nervous system, limb and midline defects have been reported in newborns exposed to statins in utero, although causality has been questioned. A 22-month-old boy with severe microcephaly, growth retardation, dysmorphic features, profound global developmental delay and peri-Sylvian polymicrogyria on brain imaging is presented. He was born to a mother exposed to telmisartan during the first seven months and rosuvastatin throughout the entire pregnancy. There were no features of fetopathy associated with sartans including telmisartan, such as a history of oligohydraminios and renal abnormalities. Given the increasing prevalence of obesity and its related complications (including dyslipidemias and hypertension) in young women of childbearing age, more safety data for prenatal exposure to statins and sartans are urgently needed.